CAC
PHAT icon

Cowen and Company’s Phathom Pharmaceuticals PHAT Stock Holding History

Cowen and Company’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-15,000
Closed -$6K – 226
2024
Q3 		$6K Buy
+15,000
New +$210K ﹤0.01% 531

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
CC
Checkpoint Capital San Francisco, California $279M AUM 45.74% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Cowen and Company's PHAT Position: Q4 2024 in Review

Cowen and Company sold out of Phathom Pharmaceuticals (PHAT) in Q4 2024, closing a stake of 15,000 shares — an estimated $271K sold.

Cowen and Company first reported a position in PHAT in Q3 2024 and held it in 1 quarter. The position peaked at $271K in Q3 2024. 144 funds tracked by Wall St. Rank hold PHAT as of Q4 2024.

  • Cowen and Company reported no remaining Phathom Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Cowen and Company sold 15,000 Phathom Pharmaceuticals shares in Q4 2024, an estimated $271K.
  • Cowen and Company first reported a position in Phathom Pharmaceuticals in Q3 2024 and held it in 1 quarter.
  • Cowen and Company's Phathom Pharmaceuticals position peaked at $271K in Q3 2024.
  • 144 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q4 2024.

Based on Cowen and Company's 13F filing for Q4 2024.